Delivery of poorly water-soluble compounds into the body and increase of their bioavailability represent a great challenge in the development of advanced nanodelivery systems, since this compounds in common dosage forms do not exert expected clinical effect, and therefore they are often abandoned early in discovery. In our research work a new nanosuspensions formulation method for poorly soluble low molecular weight drugs has been developed. Ibuprofen as a model drug was formulated as a nanosuspension using modified melt emulsification method.
COBISS.SI-ID: 1906545
A book titled Biological drugs: from gene to active ingredient describes the evolution of such drugs from the basis of molecular biology to their final clinical application. A special chapter, that is devoted to nanosized systems for delivery of peptides/proteins include liposomes, solid lipid nanoparticles, polymeric nanoparticles, polymeric micelles, dendrimers, polymeric conjugates etc. Gene delivery systems are presented as well. Well-defined formulation approach is required in this case as therapeutic genes should be delivered into the cell nucleus of a specific cell.
COBISS.SI-ID: 2122609
Cystatin as a model protein drug with antitumoral activity was incorporated into nanoparticles made of poly(lactic-co-glycolic) polymer using a double emulsion diffusion technique. By fluorescent confocal microscopy we observed that cystatin incorporated in nanoparticles rapidly entered the cells whereas free cystatin very slowly. Further, only cystatin delivered by nanoparticles effectively inhibited intracellular cathepsin B activity. A national (SI 21222 A) and international (WO 03/099262 A1) patent was granted for the process for production of nanoparticles for protein drugs.
COBISS.SI-ID: 1608305
The influence of pharmacogenetic factors and warfarin drug interactions on warfarin metabolism and maintenance dose were quantified. The patients were analysed for CYP2C9 polymorphism and S- and R-warfarin plasma concentrations, and plasma clearances were calculated. CYP2C9 genotype, age, warfarin metabolism inducers and BM contributed significantly warfarin dose requirement. The results were authorized by FDA on 16 August 2007 and are available as a part of SmPC of the medicines Coumadin tablets and Coumadin by Bristol-Myers Squibb.
COBISS.SI-ID: 1729649
Glucuronide standards were synthesized by human recombinant enzymes, isolated, purified and characterized by LC-MS/MS. The developed method was validated for an accurate and precise quantification of raloxifene and its two glucuronides in only 500 microliters of human plasma with a limit of quantification for raloxifene of just 88 pg/mL. I
COBISS.SI-ID: 2107505